A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations symbicort (budesonide/formoterol) HFA pMDI [hydrofluoroalkane pressurised metered-dose inhaler] 40/2.25 microg twice daily, with and without spacer, in children (6-11 years) with asthma.

Trial Profile

A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations symbicort (budesonide/formoterol) HFA pMDI [hydrofluoroalkane pressurised metered-dose inhaler] 40/2.25 microg twice daily, with and without spacer, in children (6-11 years) with asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2012

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2012 Actual initiation data changed from Sep 2007 to 15 Aug 2007 as reported by European Clinical Trials Database.
    • 04 Jun 2008 Astrazeneca submitted sNDA to FDA for the long-term maintenace of asthma in children 6-11 years of age.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top